CALY: A Potential Drug Target and Biomarker for Dopamine Receptor D1 Interacting Protein

Target Name: CALY

NCBI ID: G50632

CALY

CALY: A Potential Drug Target and Biomarker for Dopamine Receptor D1 Interacting Protein

Dopamine (DA) is a crucial neurotransmitter that plays a vital role in various physiological processes in the central nervous system (CNS), including motivation, pleasure, and movement control. The Dopamine receptor D1 (DRD1) is a key protein that transmits DA signals in the brain, and its function is tightly regulated by various intracellular and extracellular factors. Imbalances in DRD1 function have been implicated in various neurological disorders, including Parkinson's disease, addiction, and schizophrenia. The identification of potential drug targets and biomarkers for DRD1 has the potential to significantly advance our understanding of these disorders and inform new treatments. In this article, we will focus on the protein CALY, which has been shown to interact with DRD1 and has the potential to be a drug target or biomarker for DRD1 dysfunction.

The Dopamine Receptor D1 (DRD1)

DRD1 is a transmembrane protein that plays a central role in the transmission of DA signals in the brain. It consists of an extracellular portion (EC) and an intracellular portion (IC), which are connected by a long transmembrane region (TM). The EC region contains the N-terminus, which is involved in the formation of an interaction complex with various intracellular signaling molecules, including the neurotransmitter acetylcholine. The IC region contains the C-terminus, which contains the binding site for the neurotransmitter GDP.

DRD1 function is regulated by various intracellular and extracellular factors, including neurotransmitters, ion channels, and protein-protein interactions. The activity of DRD1 can be modulated by neurotransmitters such as GABA, which is an inhibitory neurotransmitter that can reduce the activity of DRD1. Additionally, the interaction of DRD1 with ion channels, such as the voltage-dependent K+ channels, can also be modulated by neurotransmitters. For example, the neurotransmitter dopamine (DA) can increase the activity of these channels, leading to increased neuronal excitability.

In addition to its role in neurotransmission, DRD1 is also involved in the regulation of various cellular processes, including cell survival, proliferation, and migration. It has been shown to play a role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

The Potential Role of CALY in DRD1 Function

The protein CALY has been shown to interact with DRD1 and has the potential to modulate its activity. This interaction between CALY and DRD1 has been observed in various cellular assays, including cell-free Western blotting and co-immunoprecipitation experiments. These results suggest that CALY may play a role in regulating the activity of DRD1.

Additionally, overexpression of the CALY gene has been shown to increase the activity of DRD1, potentially by increasing the levels of the neurotransmitter GDP. This increase in DRD1 activity can lead to increased neuronal excitability and the development of neurotoxicity. Therefore, CALY may be a drug target or biomarker for DRD1 dysfunction.

The Potential Use of CALY as a Drug Target

The potential use of CALY as a drug target is an exciting area of research, as it has the potential to treat various neurological disorders that are caused by imbalances in DRD1 function. One of the main targets of CAL

Protein Name: Calcyon Neuron Specific Vesicular Protein

Functions: Interacts with clathrin light chain A and stimulates clathrin self-assembly and clathrin-mediated endocytosis

The "CALY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CALY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets